Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
DGI is also hinting that there could be news of an investment from a third party soon. That could be very significant, especially if it is from their black book of HNWI business acquaintances. e.g. Elon Musk or the Murdochs etc
Here's the line..."The parties are focused on concluding definitive documentation for the JV, together with any foreign direct investment "....
Other key messaging: "I am delighted that we have entered into this MoU with EVage. EVage are a leading Indian electric vehicle manufacturer and are the perfect partner for DG Innovate to establish a large-scale manufacturing operation for our Pareta® e-drives at an expected modest cost. The proposed JV does not conflict with any of our existing collaborations and trading relationships, but is intended to provide an ideal quick route to market at scale for our technology.
"We are all focussed on concluding the JV arrangements as soon as possible and I look forward to providing further updates in due course." Peter Bardenfleth-Hansen, CEO of DG Innovate.
* Under the MoU the parties intend, subject to agreeing and entering into definitive documentation, to establish a new joint venture company (the "JV") in India.
* It is intended that the JV will manufacture a range of DG Innovate's Pareta® e-drives from a site in Chandigarh, Punjab, India, for supply to both EVage and third-party Indian customers, together with other international customers in due course.
* DG Innovate expects to benefit from both its economic interest in the JV and from licence fees from each Pareta® unit sold, including those to EVage.
* Additionally, EVage expect to source all of their electric vehicle drive requirements from the JV as soon as they are available.
* The parties are focused on concluding definitive documentation for the JV, together with any foreign direct investment and other regulatory approvals required in India, as soon as possible, with the parties targeting the start of manufacturing by the JV within the next 12 months.
* Further announcements will be made as appropriate.....
Good luck, Brighty
Exactly, "Profitable on a monthly basis" is what caught my eye. MOS is a very hard one to read as on the face of it there is huge promise but the BOD have diluted both the share price and confidence with some of their decisions to date. Still sounds an interesting business model if they get it right, which is why I'm still invested...
Good luck, Brighty
Exactly. More positive news today. All building nicely at ABDX, albeit slowly....
* Four sexually transmitted disease lateral flow self-tests complete design freeze.
* Exclusive global manufacturing plus UK and European distribution rights via strategic partnership with USA-based Find Out From Home LLC.
Good luck, Brighty
Now might be the opportune moment for Stephen Parker to be tapping his Silence Theraputics Rolodex of investors. Two of the biggest private investors during his tenure as Chairman were Richard Griffiths who held 21.9% in 2016 and Robert Keith who held 17.3% in 2016. They might have been the SAR HNWI's of 2020/2021 but if not it is surely time for Stephen Parker to hit the phones to Richard Griffiths and Robert Keith.....
Good luck, Brighty
Exactly and here's some more background for you:
* ROAD used to be known as Barkby (BARK).
* They changed their name following a JV deal with Meadow Partners last October.
* Meadow specialises in middle-market real estate transactions across all sub-sectors and risk profiles.
* Its partners have been responsible for the acquisition and ongoing asset management of over USD 30 billion of real estate assets located in the United States, Europe and Asia.
* Meadow is a real estate private equity manager based in New York and London with USD 6.2 billion gross AUM.
* Barkby / Road has been exiting its non-core investments to focus on building a portfolio of roadside real estate assets, including drive thru restaurants, convenience retail and EV charging infrastructure.
* Quality businesses are being signed up to let the units, such as Greggs.
* ROAD also has an option to increase the JV to a 10% holding. It currently has a 3% stake.
* The risk is that Meadow swallow up ROAD but the reward is that together they aim to create a £250 million modern roadside portfolio.
As I have posted over the last few months this is a slow burner that could become a sleeping giant following the Meadow Partners JV partnership...
Good luck, Brighty
Exactly from 3p to 12p in 2 hours is pretty good going. Don't forget that 3 years ago this was over 40p a share and 2 years ago it was over 25p a share. It looks as though the Barkby JV with Meadow Partners LLP was a smart move. Key clients are being signed up and new sites are being added to the portfolio....
Good luck, Brighty
Exactly a 140% rise today already. It's taken a few months and a few bumps in the road but I'm up over 100% on ROAD now. The leases are being signed with major players, such as Greggs etc, and the overall growth strategy looks encouraging. It will take a few years but this looks like it is on track to deliver an interesting roadside business. The JV was a game changer....
Good luck, Brighty
There's a reason ROAD is up over 100% today. 3 years ago this was over 40p a share and 2 years ago it was over 25p a share. For those that are unaware, ROAD, is in the process of exiting its non-core investments to focus on building a portfolio of roadside real estate assets, including drive thru restaurants, convenience retail and EV charging infrastructure. See Sky News report last September, when ROAD was called Barkby (BARK). This is a slow burner but with some good upside over the coming years....
Good luck, Brighty
ABDX confirm launch of OEM self-tests in Boots
* Boots to sell its first own brand self-tests in stores and online across the UK provided by Abingdon Health
* The global lateral flow assay market size is expected to reach USD $23 billion by 2027.
More positive news from ABDX....
Good luck, Brighty
Another £Billion + Takeover deal in our sector announced today:
* AZ acquires Fusion for 2.4 Billion
* Interesting to note that Fusion's FPI-2068 is only just moving in to Phase I clinical trials
* FPI-2265 is currently in a Phase II trial
i.e. Big bucks being paid for P1 and P2 clinical candidates....
Good luck, Brighty
Another £Billion + Takeover deal in our sector announced today:
* AZ acquires Fusion for 2.4 Billion
* Interesting to note that Fusion's FPI-2068, is only just moving in to Phase I clinical trials
* FPI-2265 is currently in a Phase II trial
i.e. Big bucks being paid for P1 and P2 candidates....
Good luck (we are going to need it), Brighty
The moment that Dr Peter Sargent joined PYC last year, first as CSO and now as CEO, conveyed a game changing moment for this little company. He's held senior management roles at global consultancy business Syneos Health Inc (NASDAQ: SYNH), & was Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK. He obviously liked what he saw at PYC and joined the company for a reason. 2024 looks a far more promising time to be invested in PYC as a result.
You would imagine from his track record that he's pretty well connected and has the ability to attract and negotiate much bigger contract awards than the previous regime. It will be interesting to hear how things are progressing at 12 Noon today.....
Good luck, Brighty
Good news: Phase 1a trial for SDC-1801 in Australia is progressing smoothly, with the Single Ascending Dose (SAD) and Food Effect study revealing no significant adverse events.....
Good luk, Brighty
I'm always positive on the Sareum science - I've made good money here - but the speed at which we are moving and the perilous financial situation they have found themselves in, mostly self-inflicted by not raising back in 2021/2022, greatly concerns me as a shareholder. We don't want to be last to the party with this. Our company needs to speed up. The FDA, five months ago, approved Bimzelx (bimekizumab-bkz) for psoriasis treatment and here in the UK Artax Biopharma has obtained clinical trial authorisation from the MHRA to assess AX-158 in a Phase IIa study in psoriasis patients. Plus SBTX (SkinBio) are considerably further ahead than Sareum in relation to approval to launch its psoriasis treatment. SBTX has already received approval from regulators to sell AxisBiotix-Ps, for psoriasis treatment, to the general public in France, Spain, Italy & here in the UK. I've already had one x24 from Sareum in 2021 by holding for 10 years in my ISA and I'm hopeful that this will be repeated again from these levels with a takeover in the coming years but we are going to really need to see a step change in the modus operandi of the BOD. They should be prepared to move aside to protect their investment as well as ours, if they are unable to progress quickly now. Afterall, TM and JR have had over 20 years at this with Sareum since 2003....
Good luck, Brighty
Exactly. It's excellent to see that FY 2024 revenues are expected to be materially higher than FY 2023 revenues of £4.0m.
Plus that revenue of £2.4m for H1 2024 more than doubled from £1.1m i.e. 117% up. That's impressive. It's all coming together here, albeit slowly...
Good luck, Brighty
Exactly Jima. Just look at the AZ deal today to acquire Amolyt Pharma, after its Phase II data for Eneboparatide proved enough for AZ to pay $1.05 billion in cash, with $800 million upfront. That's yet another $1 Billion+ deal for a clinical stage company. If SAR can start providing data then we still stand a chance of a substantial pay day. However, OUR company really does need to get its skates on before it runs out of cash. The days of dithering and waffle are over. It's time to deliver Mr Parker, Mr Mitchell and Mr Reader.....
Good luck, Brighty
One point for everyone to remember is that we've not had a negative outcome in any of our research / trials to date. Yes, the BOD have made some cataclysmic decisions on financing (in particular) and that worries even an ardent SAR supporter such as me but:
* The June 2019 data showed 100% regression of tumours in lung cancer
* The Workman / Garrett March 2020 report showed that SRA 737 when synthesised with gemcitabine had extremely encouraging results
* We've also had the data from the UKRI grant funded Covid-19 research project which showed that SDC-1801 was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib.....
For the above and because of the 2025-2029 patent expiry data that I recently posted (worth billions) I am keeping the faith. However, yes, our Chairman and CEO have some very very serious questions to answer. Sadly, the current situation is self inflicted and it is not acceptable. Waffle and radio silence won't work anymore....
Good luck, Brighty
This is a very good find and exceptionally interesting as it states that the "Principal Investigator is David Porter, MD,University of Pennsylvania". David Porter, as some of you will know on here, along with his team were indeed overseeing the CAR-T Master Translational Agreement with Penn. It would be the logical next step for Penn to recruit patients for HEMO's AML treatment.
The update confirms"Recruiting" for:
* The purpose of this study is to provide a new type of treatment for AML. This treatment combines a new type of stem cell transplant along with treatment using chimeric antigen receptor (CAR) T cells that have been engineered to recognize and attack your AML cells.
* The first treatment is a modified stem cell transplant, using blood-forming stem cells donated from a healthy donor. From the same donor, we will also make CAR T-cells, which are leukemia fighting cells, which will be given to the patient via an infusion into the vein after the transplanted stem cells have started to grow healthy blood cells. The modification of the stem cell transplant means that the healthy bone marrow cells will be "invisible" to the CAR T-cells that are trying to kill the leukemia cells.
* Official Title - Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCRζ And 4-1BB Signaling Domains In Combination With CD33KO-HSPC In Subjects With Refractory Or Relapsed Acute Myeloid Leukemia
Sounds like HEMO. If it is we should be seeing an RNS soon on the recruiting of first patients for the trial....
Good luck, Brighty
Exactly, the agreement saw HEMO grant Eli Lilly a research license for "anything jointly developed under the Agreement, as well as an option for an exclusive worldwide license to commercially exploit jointly developed materials" but Vlad / BOD walked away. Always risky to do but in the long run commercially prudent. What value do you put on world beating treatments? $Billions and $ Billions judging by the takeover deals in our sector.
Good luck, Brighty